Brief: Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety In Single Dose Portion Of Phase I Trial
22/05/2024 14:19
May 22 (Reuters) - Protagenic Therapeutics Inc PTIX.O :
* PROTAGENIC THERAPEUTICS STRESS-REGULATING PEPTIDE
DEMONSTRATES
EXCEPTIONAL SAFETY IN SINGLE DOSE PORTION OF PHASE I TRIAL
* PROTAGENIC THERAPEUTICS INC - NO CLINICALLY-RELEVANT
ADVERSE
EVENTS REPORTED IN SINGLE DOSE PORTION, MULTIPLE DOSE PORTION TO
COMMENCE
* PROTAGENIC THERAPEUTICS INC -NO CLINICALLY-RELEVANT
ADVERSE
EVENTS REPORTED IN SINGLE DOSE PORTION, MULTIPLE DOSE PORTION TO
COMMENCE
Source text for Eikon: ID:n0001493152-24-020973
Further company coverage: PTIX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Protagenic Therapeutics
See all newsBrief: Protagenic Therapeutics Inc - Alexander Arrow, CFO, To Be Terminated Effective April 30, 2026 - SEC Filing
Brief: Protagenic Therapeutics Approves Restructuring Plan on August 8- SEC Filing
Brief: Protagenic Therapeutics Granted Japanese Patent JP 7714571B
Brief: Protagenic Therapeutics Enters Share Exchange Agreement With Alterola And EMC2 - SEC Filing
Brief: Protagenic Therapeutics - May Offer And Sell, From Time To Time, Shares Of Common Stock Of Up To $1.2 Mln